1. Home
  2. CX vs UTHR Comparison

CX vs UTHR Comparison

Compare CX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cemex S.A.B. de C.V. Sponsored ADR

CX

Cemex S.A.B. de C.V. Sponsored ADR

HOLD

Current Price

$10.84

Market Cap

14.7B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$489.62

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CX
UTHR
Founded
1906
1996
Country
Mexico
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7B
20.3B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
CX
UTHR
Price
$10.84
$489.62
Analyst Decision
Buy
Buy
Analyst Count
7
12
Target Price
$10.52
$495.08
AVG Volume (30 Days)
7.3M
424.3K
Earning Date
10-28-2025
10-29-2025
Dividend Yield
0.80%
N/A
EPS Growth
231.88
16.08
EPS
0.09
26.38
Revenue
$15,869,840,000.00
$3,128,400,000.00
Revenue This Year
$2.25
$13.64
Revenue Next Year
$5.11
$5.78
P/E Ratio
$11.48
$18.55
Revenue Growth
N/A
13.50
52 Week Low
$4.89
$266.98
52 Week High
$11.05
$492.62

Technical Indicators

Market Signals
Indicator
CX
UTHR
Relative Strength Index (RSI) 63.11 68.10
Support Level $10.00 $470.13
Resistance Level $10.84 $492.62
Average True Range (ATR) 0.27 10.72
MACD 0.04 -0.53
Stochastic Oscillator 80.72 89.55

Price Performance

Historical Comparison
CX
UTHR

About CX Cemex S.A.B. de C.V. Sponsored ADR

Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: